Drug Combination Details
| General Information of the Combination (ID: C10230) | |||||
|---|---|---|---|---|---|
| Name | Epigallocatechin gallate NP Info | + | Dacarbazine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Melanoma
[ICD-11: 2C30]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | FAK | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | MMP-9 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | B16 | CVCL_F936 | Mouse melanoma | Mus musculus | ||
| In-vivo Model | Animal models were constructed by injecting intraperitoneally B16-F3m cells (2*106) into Balb/c mice. | |||||
| Experimental
Result(s) |
Combination treatment with EGCG and dacarbazine strongly inhibits melanoma growth and metastasis, and the action mechanisms of EGCG are associated with the inhibition of cell spreading, cell-extracellular matrix and cell-cell interactions, MMP-9 and FAK activities. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Inhibition of melanoma growth and metastasis by combination with (-)-epigallocatechin-3-gallate and dacarbazine in mice. J Cell Biochem. 2001;83(4):631-42. | |||
